Cited by 79RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryExtracellular vesicles in disease

Current advances in non‐viral gene delivery systems: Liposomes versus extracellular vesicles

Open access
Belhadj, Zakia, Qie, Yunkai, Carney, Randy P., Li, Yuanpei, Nie, Guangjun·2023·BMEMat

Abstract

In the past decade, nucleic acid‐based drugs have emerged as an extremely promising approach for silencing specific disease‐related genes and targeting undruggable ones. However, most nucleic acid drug therapies have not advanced to clinical practice due to their poor stability against serum enzyme degradation and cytotoxicity. Nanoscale drug delivery vehicles show potential to improve efficacy of nucleic acid drugs via targeted delivery to disease‐causing genes, yet, safe and efficient nanocarriers remain elusive. Lipid‐based nanoparticles such as liposomes (LSs) and extracellular vesicles (EVs) are among the most extensively exploited nanoscale vehicles for therapeutic cargo delivery. LS‐based nucleic acid therapies have been used for several years, with many already adopted to the clinic. More recently, EVs hold considerable promise as nucleic acid delivery vehicles due to their high biocompatibility, low immunogenicity, and the inherent abilities to interact with target cells and cross biological barriers. Moreover, a novel LS/EV hybrid gene delivery system has been engineered to preserve the benefits of both systems and generate an advanced drug delivery system. The current review focuses specifically on LS‐ and EV‐based gene therapies and provides the key advantages and shortcomings of these systems with particular emphasis on their potential use as therapeutic vectors.

Integrity signals

Registry

Crossref · 10.1002/bmm2.12018

Cites

184 of 184 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A growing body of research has illuminated the therapeutic potential of EVs derived from diverse cell types, including MSCs, iPSCs, brain-derived NSCs, ESCs, and dendritic cells.

    “A growing body of research has illuminated the therapeutic potential of EVs derived from a diverse array of cell types [207, 208]. This includes MSCs [209–211], iPSCs [212], brain-derived NSCs [213], embryonic stem cells (ESCs) [214], and dendritic cells (DC) [215].”

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Belhadj, Z., Qie, Y., Carney, R. P., Li, Y., & Nie, G.
Affiliations
  • National Center for Nanoscience and Technology (CN)
  • Second Hospital of Tianjin Medical University (CN)
  • University of California, Davis (US)
  • Chinese Academy of Sciences (CN)
Corresponding author
  • Carney, Randy P.
  • Li, Yuanpei
  • Nie, Guangjun
Venue
BMEMat
Publisher
Wiley
Published
2023-04-21
Volume
1
Issue
2
ISSN
  • 2751-7446 (ISSN-L)
  • 2751-7438
OpenAlex
W4327966055
Cited by
79
References
184
Citations by year
2026: 20 · 2025: 21 · 2024: 28 · 2023: 10
FWCI
7.04
Type
journal article
Language
en
Open access
Locations
  • BMEMat (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (31571021, 2018YFA0208900)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Keywords
non-viral gene delivery, liposomes, extracellular vesicles, nucleic acid therapeutics, lipid nanoparticles, gene silencing, nanocarriers, biocompatibility, immunogenicity, targeted delivery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review